Comparative Pharmacology
Head-to-head clinical analysis: CAPOZIDE 25 25 versus INDERIDE LA 120 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOZIDE 25 25 versus INDERIDE LA 120 50.
CAPOZIDE 25/25 vs INDERIDE LA 120/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Captopril: angiotensin-converting enzyme (ACE) inhibitor that blocks conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide: thiazide diuretic that inhibits sodium-chloride symporter in distal convoluted tubule, increasing sodium, chloride, and water excretion.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium reabsorption and promoting diuresis.
1 tablet (captopril 25 mg / hydrochlorothiazide 25 mg) orally once daily initially; may titrate up to 2 tablets per day as needed.
One capsule orally once daily, containing 120 mg propranolol HCl and 50 mg hydrochlorothiazide.
None Documented
None Documented
Captopril: ~2 hours (increased in renal impairment). Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment). Clinical context: trough effect may diminish with once-daily dosing; twice-daily dosing often used.
Propranolol: 3-6 hours; Hydrochlorothiazide: 6-15 hours. Note: Inderide LA is an extended-release formulation; effective half-life extended to approximately 8-12 hours for propranolol component.
Captopril: renal 95% (40-50% unchanged), biliary/fecal <5%. Hydrochlorothiazide: renal >95% (unchanged), biliary/fecal minimal.
Primarily hepatic metabolism (90%+), with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for negligible amounts.
Category C
Category C
ACE Inhibitor and Diuretic Combination
Beta-Blocker/Diuretic Combination